{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:29:29Z","timestamp":1774589369579,"version":"3.50.1"},"reference-count":130,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":1878,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1093\/annonc\/mdu385","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T04:39:25Z","timestamp":1411101565000},"page":"1871-1888","source":"Crossref","is-referenced-by-count":292,"title":["ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)"],"prefix":"10.1016","volume":"25","author":[{"given":"F.","family":"Cardoso","sequence":"first","affiliation":[]},{"given":"A.","family":"Costa","sequence":"additional","affiliation":[]},{"given":"L.","family":"Norton","sequence":"additional","affiliation":[]},{"given":"E.","family":"Senkus","sequence":"additional","affiliation":[]},{"given":"M.","family":"Aapro","sequence":"additional","affiliation":[]},{"given":"F.","family":"Andr\u00e9","sequence":"additional","affiliation":[]},{"given":"C.H.","family":"Barrios","sequence":"additional","affiliation":[]},{"given":"J.","family":"Bergh","sequence":"additional","affiliation":[]},{"given":"L.","family":"Biganzoli","sequence":"additional","affiliation":[]},{"given":"K.L.","family":"Blackwell","sequence":"additional","affiliation":[]},{"given":"M.J.","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"T.","family":"Cufer","sequence":"additional","affiliation":[]},{"given":"N.","family":"El Saghir","sequence":"additional","affiliation":[]},{"given":"L.","family":"Fallowfield","sequence":"additional","affiliation":[]},{"given":"D.","family":"Fenech","sequence":"additional","affiliation":[]},{"given":"P.","family":"Francis","sequence":"additional","affiliation":[]},{"given":"K.","family":"Gelmon","sequence":"additional","affiliation":[]},{"given":"S.H.","family":"Giordano","sequence":"additional","affiliation":[]},{"given":"J.","family":"Gligorov","sequence":"additional","affiliation":[]},{"given":"A.","family":"Goldhirsch","sequence":"additional","affiliation":[]},{"given":"N.","family":"Harbeck","sequence":"additional","affiliation":[]},{"given":"N.","family":"Houssami","sequence":"additional","affiliation":[]},{"given":"C.","family":"Hudis","sequence":"additional","affiliation":[]},{"given":"B.","family":"Kaufman","sequence":"additional","affiliation":[]},{"given":"I.","family":"Krop","sequence":"additional","affiliation":[]},{"given":"S.","family":"Kyriakides","sequence":"additional","affiliation":[]},{"given":"U.N.","family":"Lin","sequence":"additional","affiliation":[]},{"given":"M.","family":"Mayer","sequence":"additional","affiliation":[]},{"given":"S.D.","family":"Merjaver","sequence":"additional","affiliation":[]},{"given":"E.B.","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[]},{"given":"O.","family":"Pagani","sequence":"additional","affiliation":[]},{"given":"A.","family":"Partridge","sequence":"additional","affiliation":[]},{"given":"F.","family":"Penault-Llorca","sequence":"additional","affiliation":[]},{"given":"M.J.","family":"Piccart","sequence":"additional","affiliation":[]},{"given":"H.","family":"Rugo","sequence":"additional","affiliation":[]},{"given":"G.","family":"Sledge","sequence":"additional","affiliation":[]},{"given":"C.","family":"Thomssen","sequence":"additional","affiliation":[]},{"given":"L.","family":"van't Veer","sequence":"additional","affiliation":[]},{"given":"D.","family":"Vorobiof","sequence":"additional","affiliation":[]},{"given":"C.","family":"Vrieling","sequence":"additional","affiliation":[]},{"given":"N.","family":"West","sequence":"additional","affiliation":[]},{"given":"B.","family":"Xu","sequence":"additional","affiliation":[]},{"given":"E.","family":"Winer","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu385_bb0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.breast.2009.09.001","article-title":"Metastatic breast cancer patients: the forgotten heroes!","volume":"18","author":"Cardoso","year":"2009","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdu385_bb0015","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/annonc\/mdn424","article-title":"Prognostic factors in 1038 women with metastatic breast cancer","volume":"19","author":"Largillier","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0020","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1200\/JCO.2004.08.095","article-title":"Breast cancer with synchronous metastases: trends in survival during a 14-year period","volume":"22","author":"Andre","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdu385_bb0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1359-6349(10)70474-2","article-title":"Trends in survival in metastatic breast cancer","volume":"8","author":"Sundquist","year":"2010","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdu385_bb0030","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-011-1594-z","article-title":"Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden","volume":"130","author":"Foukakis","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdu385_bb0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.breast.2013.12.003","article-title":"Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions","volume":"23","author":"Fiteni","year":"2014","journal-title":"The Breast"},{"issue":"18","key":"10.1093\/annonc\/mdu385_bb0040","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1200\/JCO.2004.07.018","article-title":"Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer","volume":"22","author":"H\u00e9bert-Croteau","year":"2004","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1093\/annonc\/mdu385_bb0045","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2006.10.2749","article-title":"Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens","volume":"25","author":"Griggs","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdu385_bb0050","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/MLR.0b013e318178ead3","article-title":"Selecting high priority quality measures for breast cancer quality improvement","volume":"46","author":"Hassett","year":"2008","journal-title":"Med Care"},{"issue":"3","key":"10.1093\/annonc\/mdu385_bb0055","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","article-title":"1st International consensus guidelines for advanced breast cancer (ABC1)","volume":"21","author":"Cardoso","year":"2012","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdu385_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.breast.2006.11.002","article-title":"Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force","volume":"16","author":"Metastatic breast cancer","year":"2007","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdu385_bb0065","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/jnci\/djp235","article-title":"International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy","volume":"101","author":"Cardoso","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdu385_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djq029","article-title":"International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: can metastatic breast cancer be cured?","volume":"102","author":"Pagani","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1093\/annonc\/mdu385_bb0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.breast.2013.03.006","article-title":"International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)\u2013MBC Task Force: Surveillance, Staging, and Evaluation of Patients with Early-Stage and Metastatic Breast Cancer","volume":"22","author":"Lin","year":"2013","journal-title":"The Breast"},{"issue":"1","key":"10.1093\/annonc\/mdu385_bb0080","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force","volume":"129","author":"Guyatt","year":"2006","journal-title":"Chest"},{"issue":"1 suppl","key":"10.1093\/annonc\/mdu385_bb0085","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1207\/s15430154jce2101s_4","article-title":"Patient navigation: a community centered approach to reducing cancer mortality","volume":"21","author":"Freeman","year":"2006","journal-title":"J Cancer Educ"},{"key":"10.1093\/annonc\/mdu385_bb0090","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1002\/cncr.23960","article-title":"National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures","volume":"113","author":"Freund","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdu385_bb0095","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JOP.0943501","article-title":"Patient navigation through the cancer care continuum: an overview","volume":"5","author":"Hopkins","year":"2009","journal-title":"J Oncol Pract"},{"issue":"2","key":"10.1093\/annonc\/mdu385_bb0100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/NCC.0b013e3181c40401","article-title":"Patient navigation in breast cancer: a systematic review","volume":"33","author":"Robinson-White","year":"2010","journal-title":"Cancer Nurs"},{"key":"10.1093\/annonc\/mdu385_bb0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.53.6037","article-title":"Can patient navigation improve receipt of recommended breast cancer care? Evidence from the national patient navigation research program","author":"Ko","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0110","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The missing voice of patients in drug-safety reporting","volume":"362","author":"Basch","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu385_bb0115","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1016\/S1470-2045(11)70383-7","article-title":"Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Specialists (EUSOMA)","volume":"13","author":"Biganzoli","year":"2012","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1093\/annonc\/mdu385_bb0120","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.ejca.2012.10.004","article-title":"The EUSOMA recommendations for the management of young women with breast cancer","volume":"48","author":"Cardoso","year":"2012","journal-title":"Eur J Cancer."},{"issue":"3","key":"10.1093\/annonc\/mdu385_bb0125","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.breast.2014.03.011","article-title":"First international consensus guidelines for breast cancer in young women (BCY1)","volume":"23","author":"Partridge","year":"2014","journal-title":"The Breast"},{"issue":"9930","key":"10.1093\/annonc\/mdu385_bb0130","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(13)62416-2","article-title":"Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial","volume":"383","author":"Zimmermann","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1093\/annonc\/mdu385_bb0135","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.breast.2013.07.049","article-title":"Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement","volume":"22","author":"Ganz","year":"2013","journal-title":"The Breast"},{"issue":"5","key":"10.1093\/annonc\/mdu385_bb0140","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.breast.2013.07.050","article-title":"Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement","volume":"22","author":"Cardoso","year":"2013","journal-title":"The Breast"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdu385_bb0145","doi-asserted-by":"crossref","first-page":"A56","DOI":"10.1136\/bmjspcare-2014-000654.159","article-title":"Is it my last christmas dinner?\u2019 Survival of cancer patients having palliative chemotherapy during christmas period","volume":"4","author":"Silverman","year":"2014","journal-title":"BMJ Support Palliat Care"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdu385_bb0150","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.breast.2011.02.006","article-title":"Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative","volume":"20","author":"El Saghir","year":"2011","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdu385_bb0155","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1524-4741.2011.01150.x","article-title":"ACR appropriateness criteria(R) locally advanced breast cancer","volume":"17","author":"Macdonald","year":"2011","journal-title":"Breast J"},{"key":"10.1093\/annonc\/mdu385_bb0160","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2008.15.0243","article-title":"Locally advanced and inflammatory breast cancer","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0165","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1634\/theoncologist.8-6-521","article-title":"Update on locally advanced breast cancer","volume":"8","author":"Giordano","year":"2003","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdu385_bb0170","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1634\/theoncologist.2012-0039","article-title":"Inflammatory breast cancer: what we know and what we need to learn","volume":"17","author":"Yamauchi","year":"2012","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdu385_bb0175","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.breast.2011.10.005","article-title":"Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer","volume":"21","author":"Brennan","year":"2012","journal-title":"The Breast"},{"issue":"11","key":"10.1093\/annonc\/mdu385_bb0180","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1093\/annonc\/mdu385_bb0185","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(13)70502-3","volume":"14","author":"Buzdar","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0190","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"Ellis","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0195","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/cncr.21872","article-title":"Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the PRe-Operative \u2018Arimidex\u2019 Compared to Tamoxifen (PROACT) trial","volume":"106","author":"Cataliotti","year":"2006","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdu385_bb0200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10549-007-9701-x","article-title":"Letrozole in the neoadjuvant setting: the P024 trial","volume":"105","author":"Ellis","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdu385_bb0205","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0210","article-title":"Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular carcinoma of the breast","author":"Loibl","year":"2014","journal-title":"European Breast Cancer Conference"},{"key":"10.1093\/annonc\/mdu385_bb0215","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(11)70373-4","article-title":"Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial","volume":"13","author":"Masuda","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0220","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.breast.2010.08.008","article-title":"Pattern of care in locally advanced breast cancer: focus on local therapy","volume":"20","author":"Sinacki","year":"2011","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdu385_bb0225","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/annonc\/mdq345","article-title":"International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment","volume":"22","author":"Dawood","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0230","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3747\/co.20.1214","article-title":"What is the burden of axillary disease after neoadjuvant therapy in women with locally advanced breast cancer?","volume":"20","author":"Cox","year":"2013","journal-title":"Curr Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0235","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","article-title":"Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy","volume":"28","author":"Byrski","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0240","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-008-0128-9","article-title":"Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients","volume":"115","author":"Gronwald","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdu385_bb0245","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3231","article-title":"Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC)","volume":"14","author":"Byrski","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdu385_bb0250","doi-asserted-by":"crossref","unstructured":"WM Sikov DA Berry CM Perou. Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC on pathologic complete response in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) Abstr. 2013 San Antonio Breast Cancer Symposium, San Antonio, USAS5-01","DOI":"10.1158\/0008-5472.SABCS13-S5-01"},{"issue":"7","key":"10.1093\/annonc\/mdu385_bb0255","first-page":"747","article-title":"A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple- negative and HER2 positive early breast cancer (GeparSixto)","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdu385_bb0260","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10549-014-2876-z","article-title":"The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis","volume":"144","author":"Petrelli","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1093\/annonc\/mdu385_bb0265","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10549-012-2100-y","article-title":"A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM\/2006-03, multicenter study","volume":"136","author":"Alba","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1093\/annonc\/mdu385_bb0270","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.breast.2010.02.003","article-title":"Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients","volume":"19","author":"Koshy","year":"2010","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdu385_bb0275","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1210\/jcem-38-3-476","article-title":"Plasma precursors of oestrogen II. Correlation of the extent of conversion of plasma androstenedione to estrone with age","volume":"38","author":"Hemsell","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mdu385_bb0280","series-title":"Androgen Actions and Pharmacologic Uses, Endocrinology","first-page":"2232","author":"Handesman","year":"2001"},{"key":"10.1093\/annonc\/mdu385_bb0285","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejphar.2013.03.037","article-title":"An update on male breast cancer and future directions for research and treatment","volume":"717","author":"Sousa","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1093\/annonc\/mdu385_bb0290","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1524-4741.2008.00648.x","article-title":"Breast cancer in men\u2014should aromatase inhibitors become first-line hormonal treatment?","volume":"4","author":"Nordman","year":"2008","journal-title":"Breast J"},{"issue":"5","key":"10.1093\/annonc\/mdu385_bb0295","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/(SICI)1097-0142(19970901)80:5<886::AID-CNCR9>3.0.CO;2-J","article-title":"Chest wall resection in the treatment of locally recurrent breast carcinoma: indications and outcome for 44 patients","volume":"80","author":"Faneyte","year":"1997","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu385_bb0300","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0360-3016(91)90775-Y","article-title":"The results of radiation therapy for isolated local regional recurrence after mastectomy","volume":"21","author":"Schwaibold","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdu385_bb0305","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1748-717X-8-13","article-title":"Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy","volume":"8","author":"Skinner","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0310","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/1471-2407-11-197","article-title":"Re-surgery and chest wall re-irradiation for recurrent breast cancer: a second curative approach","volume":"11","author":"M\u00fcller","year":"2011","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdu385_bb0315","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.radonc.2013.11.017","article-title":"Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment","volume":"110","author":"Kilburn","year":"2014","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdu385_bb0320","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncponc0714","article-title":"The concurrent chemoradiation paradigm- general principles","volume":"4","author":"Seiwer","year":"2007","journal-title":"Nat Clin Pract"},{"key":"10.1093\/annonc\/mdu385_bb0325","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semradonc.2005.08.001","article-title":"Biologic basis for combining drugs with radiation","volume":"16","author":"Wilson","year":"2006","journal-title":"Semin Radiation Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0330","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S1053-4296(97)80024-0","article-title":"Fluoropyrimidine-radiation interactions in cells and tumors","volume":"7","author":"Lawrence","year":"1997","journal-title":"Semin Radiation Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0335","first-page":"2948","article-title":"X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine in human cancer xenografts","volume":"5","author":"Sawada","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu385_bb0340","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0360-3016(01)02740-7","article-title":"Is the therapeutic index better with gemcitabine-based chemotherapy than with 5-fluoruracil-based chemoradiation in locally advance pancreatic cancer?","volume":"52","author":"Crane","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1093\/annonc\/mdu385_bb0345","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jnci\/86.6.441","article-title":"In vitro studies of taxol as a radiosensitizer in human cancer cells","volume":"86","author":"Liebmann","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1093\/annonc\/mdu385_bb0350","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4161\/cbt.13.2.18439","article-title":"Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuzimab and nimotuzumab in A431 cells","volume":"13","author":"Gonzales","year":"2012","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"10.1093\/annonc\/mdu385_bb0355","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.ijrobp.2009.03.027","article-title":"Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase 2 trial","volume":"76","author":"Horton","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1093\/annonc\/mdu385_bb0360","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/1535-7163.MCT-09-1027","article-title":"Sensitization to radiation and alkylating agents by inhibitors of poly (ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair","volume":"9","author":"L\u00f6ser","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdu385_bb0365","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1200\/JCO.2005.05.520","article-title":"Randomized trial of hyperthermia and radiation for superficial tumors","volume":"23","author":"Jones","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1093\/annonc\/mdu385_bb0370","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0360-3016(96)00154-X","article-title":"Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials","volume":"35","author":"Vernon","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdu385_bb0375","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.radonc.2010.10.020","article-title":"Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy","volume":"97","author":"Zagar","year":"2010","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdu385_bb0380","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.1994.12.10.2071","article-title":"First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research","volume":"12","author":"Borner","year":"1994","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdu385_bb0385","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S1470-2045(13)70589-8","article-title":"Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomized trial","volume":"15","author":"Aebi","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdu385_bb0390","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.11468","article-title":"Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials","volume":"98","author":"Robertson","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdu385_bb0395","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/cncr.21163","article-title":"Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials","volume":"104","author":"Howell","year":"2005","journal-title":"Cancer"},{"issue":"10","key":"10.1093\/annonc\/mdu385_bb0400","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1093\/annonc\/mdu385_bb0405","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdu385_bb0410","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(13)70322-X","volume":"14","author":"Johnston","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdu385_bb0415","first-page":"CD003370","article-title":"Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women","author":"Gibson","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdu385_bb0420","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0425","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0430","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.COC.0000047126.10522.F9","article-title":"Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study","volume":"26","author":"Milla-Santos","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0435","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdg362","article-title":"Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer","volume":"14","author":"Paridaens","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0440","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group","volume":"21","author":"Mouridsen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0445","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","article-title":"Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group","volume":"26","author":"Paridaens","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdu385_bb0450","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu385_bb0455","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv Ther"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdu385_bb0460","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0959-8049(14)00221-4","article-title":"Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2\u2013negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2","volume":"50","author":"Piccart","year":"2014","journal-title":"Eur J Cancer"},{"issue":"22","key":"10.1093\/annonc\/mdu385_bb0465","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0470","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.lba671","article-title":"Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER-2 metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31\/GSK EGF 108919","volume":"30","author":"Gelmon","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl 9","key":"10.1093\/annonc\/mdu385_bb0475","first-page":"ixe1","article-title":"CEREBEL (EGF111438): an open label randomized phase III study comparing the incidence of CNS metastases in patients with HER2+ metastatic breast cancer, treated with lapatinib plus capecitabine versus trastzumab pluas capecitabine","volume":"23","author":"Pivot","year":"2012","journal-title":"Ann Oncol"},{"issue":"Suppl 5s","key":"10.1093\/annonc\/mdu385_bb0480","volume":"32","author":"Piccart-Gebhart","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0485","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu385_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(13)70130-X","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1093\/annonc\/mdu385_bb0495","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2011.37.4207","article-title":"Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Cort\u00e9s","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0500","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.lba1","article-title":"Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane","volume":"30","author":"Blackwell","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0505","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu385_bb0510","article-title":"T-DM1 for HER2-positive metastatic breast cancer (MBC): primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice","author":"Wildiers","year":"2013","journal-title":"Presented at the European Cancer Congress"},{"issue":"12","key":"10.1093\/annonc\/mdu385_bb0515","first-page":"008792","article-title":"Combination versus sequential single agent chemotherapy for metastatic breast cancer","author":"Dear","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1093\/annonc\/mdu385_bb0520","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2007.10.8399","article-title":"Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer","volume":"26","author":"Piccart-Gebhart","year":"2008","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1093\/annonc\/mdu385_bb0525","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1200\/JCO.2010.33.9101","article-title":"Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer","volume":"29","author":"Stockler","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0530","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10549-012-2288-x","article-title":"Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer","volume":"136","author":"Blum","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdu385_bb0535","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0540","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1023\/A:1012281104865","article-title":"Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced\/metastatic breast cancer","volume":"12","author":"O'Shaughnessy","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0545","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"29","author":"Brufsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0550","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.bjc.6600261","article-title":"Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic\/advanced breast cancer pretreated with anthracyclines","volume":"86","author":"Talbot","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdu385_bb0555","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0560","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","article-title":"Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients","volume":"92","author":"Blum","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu385_bb0565","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0570","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2010.30.8213","article-title":"Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA Study","volume":"29","author":"Andersson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdu385_bb0575","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cncr.22885","article-title":"Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study","volume":"110","author":"Burstein","year":"2007","journal-title":"Cancer"},{"issue":"9769","key":"10.1093\/annonc\/mdu385_bb0580","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"issue":"24 Suppl","key":"10.1093\/annonc\/mdu385_bb0585","article-title":"A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes","volume":"72","author":"Kaufman","year":"2012","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu385_bb0590","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-011-1648-2","article-title":"Surgery of the primary tumor does not improve survival in stage IV breast cancer","volume":"129","author":"Dominici","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdu385_bb0595","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-009-0610-z","article-title":"Loco-regional treatment in metastatic breast cancer patients: is there a survival benefit?","volume":"119","author":"Ly","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdu385_bb0600","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/cncr.24873","article-title":"Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter?","volume":"116","author":"Neuman","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu385_bb0605","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejso.2011.10.004","article-title":"Surgery in metastatic breast cancer: patients with a favorable profile seem to have the most benefit from surgery","volume":"38","author":"Rashaan","year":"2012","journal-title":"Eur J Surg Oncol"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdu385_bb0610","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0959-8049(11)70142-3","article-title":"The role of surgery in metastatic breast cancer","volume":"47","author":"Ruiterkamp","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu385_bb0615","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijrobp.2011.11.046","article-title":"Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis?","volume":"84","author":"Nguyen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdu385_bb0620","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1007\/s12032-012-0310-0","article-title":"Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression","volume":"29","author":"Petrelli","year":"2012","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdu385_bb0625","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2482-12-5","article-title":"SUBMIT: Systemic therapy with or without upfront surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation","volume":"12","author":"Ruiterkamp","year":"2012","journal-title":"BMC Surg"},{"key":"10.1093\/annonc\/mdu385_bb0630","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/jjco\/hys120","article-title":"A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017","volume":"42","author":"Shien","year":"2012","journal-title":"Jpn J Clin Oncol"},{"issue":"24 Suppl","key":"10.1093\/annonc\/mdu385_bb0635","article-title":"Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: a randomized controlled trial","volume":"73","author":"Badwe","year":"2013","journal-title":"Cancer Res"},{"issue":"24 Suppl","key":"10.1093\/annonc\/mdu385_bb0640","article-title":"Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01)","volume":"73","author":"Soran","year":"2013","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu385_bb0645","doi-asserted-by":"crossref","first-page":"R92","DOI":"10.1186\/bcr2771","article-title":"Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)","volume":"12","author":"Thompson","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdu385_bb0650","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ctrv.2011.11.006","article-title":"Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies","volume":"38","author":"Amir","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 10","key":"10.1093\/annonc\/mdu385_bb0655","doi-asserted-by":"crossref","first-page":"x349","DOI":"10.1093\/annonc\/mds297","article-title":"When to order a biopsy to characterise a metastatic relapse in breast cancer","volume":"23","author":"Foukakis","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419366335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419366335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/10\/1871\/24064848\/mdu385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:31:44Z","timestamp":1624519904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419366335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":130,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0923753419366335"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu385","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}